VIMTALABS

Vimta Labs Share Price

 

 

Invest in Vimta Labs with 1X leverage

Invest with MTF

Performance

  • Low
  • ₹419
  • High
  • ₹433
  • 52 Week Low
  • ₹400
  • 52 Week High
  • ₹903
  • Open Price₹433
  • Previous Close₹430
  • Volume153,621
  • 50 DMA₹545.49
  • 100 DMA₹581.84
  • 200 DMA₹571.84

Investment Returns

  • Over 1 Month -30.55%
  • Over 3 Month -31.73%
  • Over 6 Month -31.6%
  • Over 1 Year -18.54%

Smart Investing Starts Here Start SIP with Vimta Labs for Steady Growth!

Invest Now

Vimta Labs Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 25.4
  • PEG Ratio
  • 1
  • Market Cap Cr
  • 1,895
  • P/B Ratio
  • 4.6
  • Average True Range
  • 25.57
  • EPS
  • 17
  • Dividend Yield
  • 0.2
  • MACD Signal
  • -39.5
  • RSI
  • 29
  • MFI
  • 39.42

Vimta Labs Financials

Vimta Labs Technicals

EMA & SMA

Current Price
₹424.60
-5.3 (-1.23%)
pointer
  • Bearish Moving Average 16
  • Bullish Moving Average 0
  • 20 Day
  • ₹484.91
  • 50 Day
  • ₹545.49
  • 100 Day
  • ₹581.84
  • 200 Day
  • ₹571.84

Resistance and Support

425.37 Pivot Speed
  • R3 445.83
  • R2 439.27
  • R1 431.93
  • S1 418.03
  • S2 411.47
  • S3 404.13

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Vimta Labs Ltd. offers a wide range of testing, inspection, and analytical services, specializing in pharmaceuticals, food, and environmental testing. Serving clients globally, it provides high-quality, accredited lab services to ensure product safety and regulatory compliance.

Vimta Labs has an operating revenue of Rs. 392.49 Cr. on a trailing 12-month basis. An annual revenue growth of 10% is good, Pre-tax margin of 26% is great, ROE of 17% is exceptional. The company has a reasonable debt to equity of 1%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 69 which is a FAIR score but needs to improve its earnings, a RS Rating of 20 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at D+ which indicates heavy supply, Group Rank of 109 indicates it belongs to a poor industry group of Medical-Services and a Master Score of C is fair but needs to improve. Overall, the stock has mediocre earnings and technical strength, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Vimta Labs Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-01-28 Quarterly Results
2025-11-03 Quarterly Results
2025-07-17 Quarterly Results
2025-04-28 Audited Results, Dividend & Bonus issue
2025-01-24 Quarterly Results
Date Purpose Remarks
2025-05-30 FINAL Rs.2.00 per share(100%)Dividend
2022-06-18 FINAL Rs.2.00 per share(100%)Dividend
2021-06-28 FINAL Rs.2.00 per share(100%)Dividend
View Vimta Labs Dividend History Arrow
Date Purpose Remarks
2025-06-13 Bonus Rs.0.00 issue of equity shares in the ratio of 1:1 of Rs. 2/-.

Vimta Labs F&O

Vimta Labs Shareholding Pattern

35.9%
0%
4.59%
25.12%
34.39%

About Vimta Labs

  • NSE Symbol
  • VIMTALABS
  • BSE Symbol
  • 524394
  • Managing Director
  • Ms. Harita Vasireddi
  • ISIN
  • INE579C01029

Similar Stocks to Vimta Labs

Vimta Labs FAQs

Vimta Labs share price is ₹424 As on 07 February, 2026 | 21:29

The Market Cap of Vimta Labs is ₹1895.2 Cr As on 07 February, 2026 | 21:29

The P/E ratio of Vimta Labs is 25.4 As on 07 February, 2026 | 21:29

The PB ratio of Vimta Labs is 4.6 As on 07 February, 2026 | 21:29

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23